US 11,731,985 B2
Compositions and methods for treating cancer
Anita Bellail, Indianapolis, IN (US); Chunhai Hao, Indianapolis, IN (US); and Ho Yin Lo, Bethel, CT (US)
Assigned to Hb Therapeutics Inc., Indianapolis, IN (US)
Appl. No. 17/54,118
Filed by Hb Therapeutics Inc., Indianapolis, IN (US)
PCT Filed May 8, 2019, PCT No. PCT/US2019/031245
§ 371(c)(1), (2) Date Nov. 9, 2020,
PCT Pub. No. WO2019/217509, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/669,640, filed on May 10, 2018.
Prior Publication US 2021/0115064 A1, Apr. 22, 2021
Int. Cl. C07D 277/82 (2006.01); C07D 417/04 (2006.01); C07D 217/26 (2006.01); C07D 277/68 (2006.01); C07D 417/12 (2006.01); C07D 513/04 (2006.01); A61K 31/428 (2006.01); A61K 31/429 (2006.01); A61P 35/00 (2006.01); C07C 275/40 (2006.01); C07D 217/06 (2006.01); C07D 277/64 (2006.01)
CPC C07D 513/04 (2013.01) [A61P 35/00 (2018.01); C07C 275/40 (2013.01); C07D 217/06 (2013.01); C07D 277/64 (2013.01); C07D 277/82 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01)] 4 Claims
 
1. A compound having the following chemical structure or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry